Sign in to fuzzto save your conversations, follow your research and come back anytime.
Granules
GRANULES
NSE
BSE
NSEBSESectorHealthcare
853.85
Loading chart…
About the company
Granules India Limited is a vertically integrated pharmaceutical company founded in 1991. It manufactures Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). The company specializes in off-patent drugs and first-line defense products like Paracetamol, Ibuprofen, Metformin, and Guaifenesin. Granules India operates seven manufacturing facilities, six in India and one in the US, serving over 300 customers across 80 countries. The company has a strong focus on research and development, with a dedicated R&D center in Hyderabad. Granules India has expanded its operations through acquisitions, capacity enhancements, and the establishment of subsidiaries. It has received various regulatory approvals and certifications for its facilities and products. The company has filed numerous ANDAs, DMFs, and CEPs, and has launched several generic products in the US market.
In the news
Granules India Q1 Results: 60% profit surge drives 3% stock jump
Granules India gains 2.14% after securing FTF status for LUMRYZ generic
Granules India rises 1.69% on USFDA EIR with VAI classification
Trading Ideas: Granules, Tata Motors, CG Power & Others on May 21
Top stocks to buy: Granules, UltraTech Cement recommended
Granules India Q4 profit jumps 32% to ₹201.5 cr, stock hits record
Emkay Global recommends Granules India buy with ₹800 target
Granules India unit gets USFDA VAI classification after inspection
Granules India seeks M&A for global expansion beyond US
Granules India's Virginia facility clears USFDA inspection
Granules India Gets Second FDA Approval for ADHD Generics